Charles Schwab Investment Management Inc. Sells 68,009 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

Charles Schwab Investment Management Inc. reduced its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 16.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 349,730 shares of the biotechnology company’s stock after selling 68,009 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in REGENXBIO were worth $2,703,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in shares of REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares during the period. FMR LLC grew its stake in REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,656 shares during the last quarter. Erste Asset Management GmbH bought a new position in REGENXBIO in the 3rd quarter worth $140,000. Intech Investment Management LLC acquired a new position in REGENXBIO during the 3rd quarter worth $161,000. Finally, BNP Paribas Financial Markets boosted its holdings in REGENXBIO by 602.9% during the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 17,533 shares during the period. Institutional investors own 88.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on RGNX. Morgan Stanley lifted their price objective on REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, March 14th. Leerink Partners set a $24.00 price target on REGENXBIO in a research report on Tuesday, March 18th. Chardan Capital reissued a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Thursday, March 20th. The Goldman Sachs Group downgraded shares of REGENXBIO from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $38.00 to $14.00 in a research note on Tuesday, February 11th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $30.00 target price on shares of REGENXBIO in a research note on Tuesday, January 21st. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.78.

REGENXBIO Price Performance

Shares of RGNX stock opened at $7.91 on Friday. REGENXBIO Inc. has a one year low of $5.62 and a one year high of $22.42. The stock has a fifty day moving average price of $7.39 and a 200 day moving average price of $8.81. The stock has a market cap of $396.18 million, a P/E ratio of -1.57 and a beta of 1.35.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $21.21 million during the quarter, compared to analysts’ expectations of $23.70 million. Equities research analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.